Re-Aim Therapeutics Overview

  • Year Founded
  • 2024

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Seed

  • Latest Deal Amount
  • $9.5M

  • Investors
  • 3

Re-Aim Therapeutics General Information

Description

Developer of targeted biologics designed to address autoimmune diseases by depleting pathogenic T-cell subsets involved in chronic inflammation and disease progression. The company offers integration of pathway signatures with membrane targets to identify precise T cells, applies drugging of functional epitopes within disease contexts, and combines antibody discovery expertise with advisory input, enabling healthcare providers and researchers to access selective therapies that improve disease management and expand treatment options for autoimmune conditions.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Innovation Building, Old Campus Road
  • Oxford
  • England, United Kingdom
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Innovation Building, Old Campus Road
  • Oxford
  • England, United Kingdom

Re-Aim Therapeutics Timeline

20252026
Date FoundedFinancing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Re-Aim Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Seed Round 18-May-2026 $9.5M Completed Product Development
1. Angel (individual) 28-Mar-2025 Completed Startup
To view Re-Aim Therapeutics’s complete valuation and funding history, request access »

Re-Aim Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series Seed
Ordinary
To view Re-Aim Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Re-Aim Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Re-Aim Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
Oxford Science Enterprises Venture Capital Minority
Syncona Venture Capital Minority
NG Bio (UK) Venture Capital Minority
To view Re-Aim Therapeutics’s complete investors history, request access »

Re-Aim Therapeutics FAQs

  • When was Re-Aim Therapeutics founded?

    Re-Aim Therapeutics was founded in 2024.

  • Where is Re-Aim Therapeutics headquartered?

    Re-Aim Therapeutics is headquartered in Oxford, United Kingdom.

  • What is the size of Re-Aim Therapeutics?

    Re-Aim Therapeutics has 3 total employees.

  • What industry is Re-Aim Therapeutics in?

    Re-Aim Therapeutics’s primary industry is Drug Discovery.

  • Is Re-Aim Therapeutics a private or public company?

    Re-Aim Therapeutics is a Private company.

  • What is the current valuation of Re-Aim Therapeutics?

    The current valuation of Re-Aim Therapeutics is .

  • What is Re-Aim Therapeutics’s current revenue?

    The current revenue for Re-Aim Therapeutics is .

  • How much funding has Re-Aim Therapeutics raised over time?

    Re-Aim Therapeutics has raised $9.8M.

  • Who are Re-Aim Therapeutics’s investors?

    Oxford Science Enterprises, Syncona, and NG Bio (UK) have invested in Re-Aim Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process